Adani Ports breaks out at record Rs 1,747 as 500 MMT milestone meets Hormuz reroute trade (NSE: ADANIPORTS)
Read More Pharma Industry News Does Priority Review signal a commercial breakthrough for Protagonist Therapeutics, Inc.? Takeda and Protagonist secure FDA Priority Review for rusfertide in PV. Explore the strategic, financial, and competitive implications now. bySoujanya RaviMarch 5, 2026